All articles

DSIP: the delta sleep-inducing peptide and what the studies showed

What this peptide is and what studies showed about it

What it is

A short chain of nine links that was called the sleep peptide.

  • a small molecule of the protein type
  • the name comes from the first experiments of the 1970s
  • it has an official name: emideltide

Where the name comes from

The name promises deep sleep, but in the studies the picture is more modest.

  • in one controlled study only light sleep increased
  • deep sleep and dreaming sleep stayed the same
  • the name turned out louder than the result

What was measured in insomnia

Sleep was recorded with instruments, and people were asked themselves.

  • how quickly they fall asleep
  • how long they sleep and how often they wake
  • how the person rates their own sleep

What came out

How people felt barely changed in the controlled studies.

  • in the placebo-controlled study sleep was rated the same as before
  • the positive numbers came from studies without a placebo
  • almost all of them were done by one group of authors

What was not found

No daytime heaviness was noted after a night with the substance.

  • in one small study daytime performance did not decline
  • it was not compared with sleeping pills, though
  • its effect on night sleep is modest

Stress and cortisol

The stress hormone did not change with the substance.

  • a pituitary hormone fell in one study
  • cortisol itself stayed the same
  • in the second study nothing changed

Pain and withdrawal

Here the studies are very small.

  • for pain there is one small open study
  • in opiate and alcohol withdrawal the study was open, with no comparison
  • a repeat check by another group showed less

How it was given in studies

In the work on sleep, pain and withdrawal: into a vein, slowly.

  • the infusion took several minutes
  • with a very fast infusion there was no effect
  • the course lasted from one day to two weeks

An injection under the skin

This is how the substance is sold, but it was not given this way in clinical studies.

  • the studies were done differently
  • the safety of subcutaneous injections is not described in the studies
  • a nasal spray was used in two small studies

What the regulator says

It is not a registered medicine.

  • the American regulator assessed the substance in 2026
  • it proposed not adding it to the list for pharmacies
  • the quality of the forms on sale is not confirmed

Who should see a doctor first

Insomnia, pain and dependence have different causes.

  • blood pressure: some drugs change how the substance is broken down
  • pregnancy and breastfeeding
  • any insomnia lasting longer than a few weeks

Important. Such a substance is not prescribed without an examination and a look at the cause of the sleep problem.

The main point

A substance with a nice name and modest results.

  • night sleep changed only slightly
  • in a small study no daytime heaviness was noted
  • the decision is made by a doctor after finding the cause

Frequently asked questions

It is a peptide of 9 amino acids, with the official international name emideltide. It is not an ingredient of any FDA-approved drug and is not a registered medicine in any country the FDA checked (FDA document of 11.05.2026).

In a placebo-controlled crossover study with sleep recording (6 people, 1 study), only the second, light stage rose, while the third and fourth stages (deep sleep) and REM did not change (Monti JM Int J Clin Pharmacol Res 1987. PMID 3583493).

In a double-blind placebo-controlled study (16 people, 1 study), sleep efficiency and falling asleep were slightly better, and subjective sleep quality did not change (PMID 1299794). The large numbers come from a series of 14 people, where the same people received placebo on separate nights and the comparison was with an outside group of healthy people: falling asleep went from 58.4 to 27.6 minutes (PMID 3622582; FDA review, p. 26).

Cortisol did not change at 25 nmol/kg (11 people, 1 study; PMID 2554357) or at 3–4 mg (20 people, 2 experiments; PMID 7777652). Stress scales were not used in these studies.

Intravenously and slowly, most often 25 nmol/kg (about 1.5 mg for 70 kg), as a course of 1 to 15 days. The authors named 4–8 minutes as the optimal infusion time; with a 1-minute infusion there was no effect (Schneider-Helmert D Neuropsychobiology 1983. PMID 6689058).

In the studies, about 1.5–2.1 mg was given intravenously in a clinic. The product on sale is for subcutaneous injection and nasal spray, in 5 mg vials. According to the FDA, there are no subcutaneous clinical studies, and certificates of analysis did not always match the declared substance.

In withdrawal in 107 people, 95 had no significant adverse events, 9 had mild ones and 3 had serious ones, including hypotension (Dick P Eur Neurol 1984. PMID 6548969; the safety numbers are from the FDA review, p. 51; the abstract of the study itself names only headaches in a few people). In total, 209 people received the substance (FDA document, p. 51).

In an uncontrolled open study (107 people, 1 study), improvement was noted in 97 % of the opiate and 87 % of the alcohol patients who were assessed; the rating was given by doctors and nurses without standard scales (PMID 6548969). In a repeat study (7 people, 1 study), 2 people completed the regimen (PMID 9617990).

Share
Follow on TelegramGet new articles, research updates and practical health tips
Читать на русскомЧитати українською

This article is for informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your physician before making health decisions. Full disclaimer

Ready to Take Action?

A consultation starts where the article ends: your history, your labs, a plan for your case.

Book consultationAsk a question